secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001823239-23-000037
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q1 revenue $79M, down 68% YoY; net loss $1.3M vs prior net income $146.9M
--------------------------------------------------------------------------------

- Revenue $79.0M, -67.7% YoY; net loss $(1.3)M vs net income $146.9M in Q1 2022.
- Nucleic Acid Production revenue $61.5M (-72.5% YoY) includes ~$15.9M COVID-19 CleanCap revenue, $157M less YoY.
- Biologics Safety Testing revenue $17.6M (-14.9% YoY) driven by post-COVID inventory normalization and China slowdown.
- Adjusted EBITDA $23.8M (30.1% margin), down from $187.0M in prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323923000037/0001823239-23-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323923000037/mrvi-20230508.htm
  HTML page:      https://secwatch.observer/filing/0001823239-23-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer